Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. It serves its products through stockists, doctors, pharmacies, chemists, large government, semi-government institutions, missionary hospitals, and public sector enterprises. It exports its products. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.
Metrics to compare | JENA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJENAPeersSector | |
---|---|---|---|---|
P/E Ratio | 15.5x | 31.3x | −0.5x | |
PEG Ratio | 0.99 | 0.32 | 0.00 | |
Price/Book | 2.9x | 3.9x | 2.6x | |
Price / LTM Sales | 3.2x | 3.8x | 3.3x | |
Upside (Analyst Target) | - | 13.0% | 40.3% | |
Fair Value Upside | Unlock | −7.1% | 4.7% | Unlock |